Convert Pharmaceuticals

Convert Pharmaceuticals is a preclinical-stage drug development company building a proprietary drug pipeline that leverages specific factors of the tumor microenvironment for therapeutic benefit. Convert’s lead product is a Hypoxia-Activated Prodrug (HAP). Hypoxia represents a therapeutic barrier as it promotes the development of resistance to conventional anti-cancer therapies. Convert Pharmaceuticals combines proprietary insights into the tumor microenvironment with expertise in drug and biomarker development to create effective and well-tolerated HAPs. Advanced biomarker research allows for detailed stratification to treat well-defined patient populations.